Antibody Therapeutics for Life

Notices


No Title Written by Written date Inquire
47   PharmAbcine, a clinical stage immuno-oncology company announced that PharmAbcine is so proud to be a sponsor of the 11th COGNO Annual Scientific Meeting,   관리자   2019-01-14   2,571  
46   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to present at the 73rd Annual Conference of KAOBS.   관리자   2019-01-14   177  
45   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine has presented as invited speaker at GBC 2018 on June 26-29, 2018   관리자   2019-01-14   168  
44   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited as a chairman of the session of the antibody therapeutics at BIOPLUS 2018 on September 6-9, 2018.   관리자   2019-01-14   180  
43   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to give a presentation as a speaker and panelist at AFOB SUMMER FORUM 2018   관리자   2019-01-14   178  
42   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is attending ASCO 2018.   관리자   2019-01-14   168  
41   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine and Dr. Sung Woo Kim, Head of Business Development are attending BIO 2018.   관리자   2019-01-14   163  
40   PharmAbcine, a clinical stage immune-oncology company, today announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to present at the company presentation session at BIO 2018.   관리자   2019-01-14   159  
39   PharmAbcine Announces FDA Orphan Drug Designation Granted to TTAC-0001 for Glioblastoma Multiforme.   관리자   2019-01-14   156  
38   `` Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model`` is now indexed on PubMed.   관리자   2019-01-14   164